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A B S T R A C T
Background: Recent clinical trials have demonstrated the efﬁcacy of short-term treatment with
tolvaptan, an oral vasopressin V2 receptor antagonist, in patients with heart failure. However, the
response to tolvaptan varies among patients. The aim of this study was to determine factors associated
with response to tolvaptan in patients with acute decompensated heart failure (ADHF).
Methods: The Tolvaptan Registry, a prospective, observational, multicenter cohort study performed in
Japan, aims to determine factors affecting the responsiveness of tolvaptan in patients with ADHF. We
enrolled ADHF patients treated with tolvaptan and they were divided into two groups: responders and
non-responders. Responders were deﬁned as subjects who met all of the following three conditions: (1)
increasing urine volume during a 24-hour period after the start of tolvaptan treatment; (2) improvement
in New York Heart Association functional class; and (3) decrease in cardiothoracic ratio assessed by chest
X-ray on day 3 of tolvaptan administration.
Results: Among the 114 patients, treatment with tolvaptan improved three conditions of heart failure in
more than half of all the cohorts (71 patients, 62%). As for baseline characteristics, estimated glomerular
ﬁltration rate, urine osmolality, and kidney size were signiﬁcantly greater in responders than in non-
responders. Multivariate logistic analysis revealed that kidney size was independently associated with
responders (odds ratio: 1.083, p = 0.001, 95% conﬁdence interval 1.031–1.137).
Conclusions: The main clinical characteristic of responders to treatment with tolvaptan is that kidney
size is preserved.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Heart failure (HF) is characterized by ﬂuid overload. Non-
potassium-sparing diuretics including loop and thiazide diuretics
are used for treatment of ﬂuid overload. However, natriuretic
therapy alone is sometimes insufﬁcient to control ﬂuid retention
[1]. Furthermore, it leads to activation of neurohormones and
serum electrolyte depletion. Tolvaptan is an oral vasopressin V2 reserved.
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that short-term treatment with tolvaptan in addition to standard
therapy including diuretics increased urine volume, decreased
body weight, and improved many heart failure symptoms in
patients with acute decompensated heart failure (ADHF) [2–
5]. Thus, treatment with tolvaptan is expected to be helpful in
reducing the length of hospital stay.
However, the response to tolvaptan varies among patients and
is sometimes unpredictable [6,7]. Imamura et al. showed that urine
osmolality can predict increase in 24-h urine volume after
treatment with tolvaptan in patients with ADHF [7,8]. We should
consider the renal function or reserve in predicting the response to
tolvaptan. Serum creatinine or estimated glomerular ﬁltration rate
(eGFR), however, is not sufﬁcient for predicting responders in HF
patients [7,8]. Tubular mechanisms are also important to enhance
water retention during HF [9]. Aldosterone activates sodium-
retaining channels in the collecting tubule, and arginine vasopres-
sin via the V2 receptor promotes water reabsorption by inserting
aquaporin-2 water channels into the luminal membrane of the
collecting tubule. Moghazi et al. showed that kidney size is
inversely correlated with glomerular sclerosis and tubular atrophy.
Kidney size is one of the simple estimates of renal reserve and
function of collecting tubules [10].
The aim of this study was to determine the characteristics of
responders to tolvaptan in patients with ADHF by use of variables
including new factors.
Materials and methods
Patient population
The Tolvaptan Registry, a prospective, observational, multicenter
cohort study performed in Japan, aims to determine factors affecting
the responsiveness of tolvaptan in patients with ADHF. The
Tolvaptan Registry enrolled ADHF patients treated with tolvaptan
from August 2011 to December 2013 in 7 hospitals throughout
Japan. We retrospectively analyzed data from the Tolvaptan Registry
and evaluated the effectiveness of tolvaptan in ADHF patients.
All of the patients had evidence of pulmonary congestion or
pleural effusion on chest X-rays and symptoms of heart failure
corresponding to New York Heart Association (NYHA) functional
classes II to IV. In the present study, we enrolled patients
who underwent thoracic and abdominal multi detector-row
computed tomography (MDCT). We excluded patients who did
not undergo MDCT (Exclusion 1, Fig. 1). Indications for CTFig. 1. Patient selection ﬂow diagram. Of the 159 patients registered in the
Tolvaptan Registry, a total of 45 patients were excluded from this analysis because
of insufﬁcient data collection or exclusion criteria. Data for 114 patients were
analyzed in this study. MDCT, multi detector-row computed tomography; ADHF,
acute decompensated heart failure.examinations are stated in practice parameters of the American
College of Radiology and we performed MDCT according to the
statements [11]. Thoracic MDCT was performed to screen for
pneumonia, pleural effusion, and calciﬁcation of the coronary
artery. The reasons for performing abdominal MDCT were not for
evaluation of kidney size but for clariﬁcation of ﬁndings from
laboratory abnormalities, evaluation of abdominal ﬂuid collec-
tions, and assessment of abnormalities of abdominal or pelvic
vascular structures [11]. We excluded patients who had severe
hypotension [supine systolic blood pressure (SBP) < 80 mmHg]
and who were treated with hemoﬁltration or dialysis. Patients
with acute coronary syndrome were also excluded (Exclusion 2,
Fig. 1). Furthermore, we excluded patients for whom the dose of
tolvaptan was changed during a period of 3 days after the start of
tolvaptan treatment and patients for whom the doses of diuretics
except for tolvaptan were changed during a period of 24 h after
the start of tolvaptan treatment (Exclusion 2, Fig. 1). The present
study complied with the Declaration of Helsinki, and the
institutional review board of Okayama University Graduate
School of Medicine approved the research protocol [the applica-
tion number 449]. Informed consent was obtained from all
patients before enrollment.
Study protocols
The initial tolvaptan dose was 3.75 mg to 15 mg/day, and the
same dose of tolvaptan was maintained for 3 days. Baseline
clinical data were obtained within 24 h before administration of
tolvaptan. Left ventricular ejection fraction (LVEF) was assessed
by transthoracic echocardiography [12], and eGFR was deter-
mined by the modiﬁed Modiﬁcation of Diet and Renal Disease
study formula (MDRD) for Japanese: eGFR = 194  (age0.287) 
(serum creatinine1.094)  (0.739 if female) [13]. To assess kidney
size, we measured the longest longitudinal length of the kidney on
each side in coronal section images of MDCT before tolvaptan
administration. We deﬁned kidney size as the mean longitudinal
length on the two sides (Fig. 2). Clinical assessments consisting of
urine volume, body weight, NYHA class, markers of renal function
and electrolytes, and cardiothoracic ratio (CTR) assessed by chest
X-ray were performed before and 3 days after tolvaptan
administration. In this study, chest X-rays were taken in the
supine or sitting position at end-inspiration. Comparisons were
made for patients in the same conditions. During tolvaptan
administration, patients were allowed to drink water freely.
Urine volume was measured every 24 h during tolvaptan
administration.
Deﬁnition of responders
Patients were classiﬁed into two groups: responders and non-
responders. Responders were deﬁned as subjects who met all of
the following three conditions: (1) increasing urine volume
during a 24-h period after the start of tolvaptan treatment; (2)
improvement in NYHA functional class; and (3) decrease in
cardiothoracic ratio assessed by a chest X-ray on day 3 of
tolvaptan administration. In all of the patients included in this
study, ﬂuid retention was one of the causes of heart failure, and
diuretics were necessary for reduction of ﬂuid retention. Fluid
retention causes enlargement of the right-side heart and increase
in CTR. It has been reported that CTR reﬂected right-sided rather
than left-sided cardiomegaly [14]. Other investigators have
reported that high CTR at baseline as measured by a chest
X-ray was a marker of poor prognosis [15]. Therefore, reduction of
CTR indicates reduction of ﬂuid in the body and contributes to
improvement in prognosis. We therefore used CTR as one of the
deﬁnitions of responder.
Fig. 2. Measurement of kidney size with coronal section images of multi detector-row computed tomography. The longest longitudinal length of the kidney on each side was
measured. We deﬁned kidney size as mean longitudinal length on the two sides. (A) Representative image of the longest longitudinal lengths of the two kidneys on the same
section in a male responder. Kidney size was deﬁned as mean kidney length. The patient’s eGFR was low (40.8 mL/min/1.73 m2), but his kidney size was normal (10.4 cm). (B)
Representative images of the longest longitudinal lengths of the right (a) and left (b) kidneys of a male non-responder. Kidney size was deﬁned as mean kidney length. The
patient’s eGFR was 57.2 mL/min/1.73 m2, but his kidney was atrophic (7.2 cm). eGFR, estimated glomerular ﬁltration rate.
Fig. 3. Patient enrollment. The patients (72  15 years, 65 men) were divided into two
groups: 71 patients (62%) were responders and 43 patients were non-responders.
ADHF, acute decompensated heart failure; NYHA, New York Heart Association; CTR,
cardiothoracic ratio.
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Statistical analysis was performed using SPSS 11.0 for Windows
(SPSS, Chicago, IL, USA). All data are expressed as mean  standard
deviation (SD) and the mean differences between groups were
analyzed using Student’s t-test. Proportional differences were analyzed
using Fisher’s exact analysis. Categorical variables were analyzed using
the chi-squared test. We conducted one-way analysis of variance
(ANOVA) by considering data multiplicity over time, and used
Wilcoxon’s signed rank test to compare NYHA before treatment and
that after treatment. We calculated odds ratios (OR) derived from the
logistic regression model to predict responders. All baseline variables
were included in logistic regression analyses. Multivariate analysis
was performed using all variables with p < 0.05 in univariate analysis.
A p-value of <0.05 was considered signiﬁcant.
Results
Effects of tolvaptan
Of the 159 patients registered in the Tolvaptan Registry, a total
of 45 patients were excluded from this analysis because of
insufﬁcient data collection or exclusion criteria (Fig. 1). Data for
114 patients were analyzed in this study (Table 1 and Figs. 1 and 3).
More than half of the patients with ADHF were responders
[number of responders: 71 (62%)]. We analyzed the overall effects
of tolvaptan on the three conditions to clarify the details of the
effect on each condition.
Urine volume: The urine volume in 16 of the 114 patients did
not increase (Fig. 3), but the mean urine volume signiﬁcantlyincreased on day 1 of tolvaptan administration in both groups
(71 responders, day 0: 1274  646 mL versus day 1: 2627 
1040 mL, p < 0.001; 43 non-responders, day 0: 1302  721 mL versus
day 1: 1996  889 mL, p < 0.05) (Fig. 4A). However, the urine volume
for each of the 3 days was signiﬁcantly greater in responders than in
non-responders (day 1, responders versus non-responders:
Table 1
Baseline characteristics according to responsiveness to treatment with tolvaptan
(n = 114).
Responders
(n = 71)
Non-responders
(n = 43)
p-value
Demographic variables
Average dose of
tolvaptan (mg/day)
10.1  3.7 9.4  3.6 0.344
Initial dose of tolvaptan n (%)
3.75 (mg) 1 (1.4) 2 (4.7)
7.5 (mg) 45 (63.4) 29 (67.4)
15 (mg) 25 (35.2) 12 (27.9)
Age, years 71.6  15.4 73.2  14.1 0.580
Male gender, n (%) 44 (62.0) 20 (46.5) 0.109
Clinical measures
Height, cm 158  10 155  10 0.178
Weight, kg 58.6  11.7 54.5  12.2 0.109
Body mass index 23.3  3.3 22.2  4.0 0.151
Systolic blood
pressure, mmHg
111.0  17.1 112.1  24.8 0.789
Diastolic blood
pressure, mmHg
63.5  13.4 63.1  15.7 0.896
Heart rate, bpm 83.1  23.6 80.1  25.1 0.527
SpO2, % 96.3  8.5 95.7  4.8 0.654
NYHA n (%) 0.611
II 5 (7.0) 6 (14.0)
III 47 (66.2) 25 (58.1)
IV 19 (26.8) 12 (27.9)
Cardiothoracic ratio, % 65  6 66  5 0.345
LVEF, % 39.5  16.2 42.0  18.2 0.462
Kidney size, cm 9.3  1.1 8.3  1.2 <0.001
Underlying heart diseases
Ischemic Heart
disease, n (%)
16 (22.5) 4 (9.3) 0.051
Valvular heart
disease, n (%)
21 (30.0) 10 (23.3) 0.467
Cardiomyopathy, n (%) 21 (30.0) 14 (32.6) 0.741
Hypertensive heart
disease, n (%)
5 (7.0) 4 (9.3) 0.668
Others, n (%) 10 (13.7) 11 (25.6) 0.041
Medical history
Hypertension, n (%) 35 (49.3) 26 (60.5) 0.249
Diabetes mellitus, n (%) 24 (33.8) 19 (44.2) 0.279
Dyslipidemia, n (%) 24 (33.8) 13 (30.2) 0.696
Concomitant medications (at index admission)
Digoxin, n (%) 7 (10) 7 (16) 0.342
ACEI/ARB, n (%) 41 (58) 24 (56) 0.842
Ca antagonist, n (%) 11 (15) 14 (33) 0.047
b blocker, n (%) 37 (52) 26 (60) 0.388
Diuretics, n (%) 68 (96) 41 (95) 0.915
Furosemide, mg/day 45.9  26.2 46.5  25.2 0.905
Vasoactive agonist (%)
Dopamine, n (%) 6 (8) 3 (7) 0.78
Dobutamine, n (%) 15 (21) 8 (19) 0.748
Carperitide, n (%) 9 (13) 9 (21) 0.27
Nitroglycerine/
isosorbide, n (%)
2 (3) 3 (7) 0.354
Laboratory parameters
Total bilirubin, mg/dL 1.0  0.9 1.0  0.8 0.904
Serum albumin, g/dL 3.4  0.5 3.4  0.6 0.925
C-reactive protein, mg/dL 1.51  2.35 1.98  2.44 0.311
Hemoglobin, g/dL 11.2  2.2 10.6  1.9 0.167
Uric acid, mg/dL 7.4  2.5 7.9  2.6 0.297
Serum sodium, mEq/L 137  7 137  5 0.869
Serum potassium, mEq/L 4.2  0.6 4.5  0.6 0.017
Plasma BNP, pg/mL
median (IQR)
906 (392–1223) 996 (395–1207) 0.622
Serum BUN, mg/dL 28.8  16.4 37.8  17.0 0.006
Serum creatinine, mg/dL 1.36  0.65 1.65  0.68 0.025
eGFR, mL/min/1.73 m2 47.8  25.7 34.3  17.1 0.003
Serum osmolality,
mOsm/L
293.9  26.4 297.4  21.8 0.595
Urine osmolarity,
mOsm/L
445.5  166.3 368.2  90.0 0.02
Data are given as mean  SD or number (%). NYHA, New York Heart Association;
LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin-receptor blocker; BNP, brain natriuretic peptide; BUN,
blood urea nitrogen; eGFR, estimated glomerular ﬁltration rate.
Fig. 4. Effects of tolvaptan. (A) Changes in urine volume in responders and non-
responders. Mean urine volume was signiﬁcantly increased on days 1 and 2 of
tolvaptan administration in non-responders. *p < 0.05 versus urine volume on day
0 in non-responders. Mean urine volume signiﬁcantly increased during the 3 days of
tolvaptan administration in responders. **p < 0.001 versus urine volume on day 0 in
responders. Urine volume was signiﬁcantly greater in responders than in non-
responders during the 3 days of treatment. Data are mean  standard deviation. (B)
Changes in NYHA class in responders and non-responders. Median NYHA class was
signiﬁcantly decreased on day 3 of tolvaptan administration in both groups. NYHA
class was signiﬁcantly lower in responders than in non-responders on day 3 of
tolvaptan treatment. #p < 0.001 versus NYHA class on day 3 in non-responders. (C)
Changes in CTR. CTR in responders was signiﬁcantly decreased after tolvaptan
treatment, but it was not decreased in non-responders. CTR was signiﬁcantly lower
in responders than in non-responders on day 3 of tolvaptan treatment.
##p < 0.0001 versus CTR on day 3 in non-responders. Data are mean  standard
deviation. NYHA, New York Heart Association; CTR, cardiothoracic ratio.
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ers: 1960  1011 mL, p < 0.01; day 3, responders: 2259  818 mL
versus non-responders: 1838  869 mL, p < 0.05). Body weight
reductions from day 0 to 3 were signiﬁcantly greater in responders
than in non-responders (responders: 2.2  1.7 kg versus non-
responders: 0.7  1.6 kg, p < 0.001).
NYHA class: NYHA class did not improve in 16 of the 98 patients
with increasing urine volume (Fig. 3). Therefore, the condition of
increasing urine volume is not sufﬁcient to deﬁne responders to
tolvaptan in a clinical setting. In addition to increase in urine
H. Toda et al. / Journal of Cardiology 67 (2016) 177–183 181volume, improvement in heart failure symptoms including
improvement in NYHA functional class or signs such as decrease
in CTR is important in treatment of ADHF. Improvements in mean
NYHA class in responders and non-responders are shown in Fig. 4B.
NYHA class did not change in 22 of the 43 non-responders (Fig. 4B),
but median NYHA class was signiﬁcantly decreased on day 3 of
tolvaptan administration in both groups (responders, day 0:
3.2  0.6 versus day 3: 2.2  0.5, p < 0.001; non-responders, day 0:
3.1  0.6 versus day 3: 2.6  0.6, p < 0.05). Finally, NYHA class was
signiﬁcantly lower in responders than in non-responders on day 3 of
tolvaptan treatment (responders: 2.2  0.5 versus non-responders:
2.6  0.6, p < 0.001).
Cardiothoracic ratio: As shown in Fig. 4C, CTR in responders was
signiﬁcantly decreased after tolvaptan treatment, but it was not
decreased in non-responders (responders, day 0: 65  6 versus day
3: 61  6, p < 0.0001; non-responders, day 0: 61  5 versus day 3:
67  6, p = NS). Finally, CTR was signiﬁcantly lower in responders
than in non-responders on day 3 of tolvaptan treatment (responders
versus non-responders on day 3, p < 0.0001).
Baseline characteristics according to responsiveness to treatment with
tolvaptan
As shown in Table 1, there were no signiﬁcant differences
between responders and non-responders in baseline character-
istics including age, sex, body mass index (BMI), SpO2, NYHA
functional class, CTR, LVEF, underlying heart diseases, medical
history, and laboratory parameters such as serum C-reactive
protein, hemoglobin, uric acid, serum sodium, and plasma BNP
levels. There were also no signiﬁcant differences in the doses of
tolvaptan between responders and non-responders. As for
laboratory parameters concerning kidney function, there were
signiﬁcant differences in serum blood urea nitrogen, serum
creatinine, eGFR, and urine osmolality between the two groups.
Kidney size assessed by longitudinal length of the kidney (Fig. 2)
was signiﬁcantly greater in responders than in non-responders
(longitudinal kidney size of responders versus non-responders:
9.3  1.1 cm versus 8.3  1.2 cm, p < 0.001).
In cases of increasing urine volume on the ﬁrst day, the doses of
other diuretics were not changed for three days. Patients who
showed no increase in urine volume in the ﬁrst 24 hours wereTable 2
Independent predictors of responsiveness to treatment with tolvaptan.
Univariate analysis 
OR 95% CI 
Age 1.283 1.024–1.608 
Sex 0.107 0.001–7.793 
Height 1.187 0.864–1.63 
Weight 0.934 0.723–1.205 
Systolic blood pressure 1.057 0.958–1.167 
Diastolic blood pressure 0.913 0.777–1.072 
Heart rate 0.937 0.84–1.045 
Cardiothoracic ratio 0.964 0.733–1.268 
LVEF 0.877 0.765–1.005 
Tolvaptan dose 1.253 0.774–2.03 
Furosemide dose 1.064 0.983–1.151 
Hypertension 0.259 0.001–6.634 
Diabetes mellitus 1.934 0.08–46.95 
Serum albumin 1.811 0.157–20.94 
C-reactive protein 1.139 0.449–2.888 
Hemoglobin 1.444 0.621–3.357 
Serum sodium 1.432 0.993–2.064 
Plasma BNP 0.111 0.001–5.068 
eGFR 1.106 1.004–1.219 
Urine osmolarity 1.005 0.994–1.015 
Kidney size 1.328 1.03–1.712 
OR, odds ratio; CI, conﬁdence interval; LVEF, left ventricular ejection fraction; BNP, bcategorized as non-responders. In non-responders, the doses of
other diuretics were probably increased 24 h later according to the
judgment of each medical doctor. However, changes in doses of
other diuretics were unknown, and change in dose did not
contribute to the results of this study.
Independent predictors of responsiveness to treatment with tolvaptan
Results of univariate and multivariate linear regression
analyses of factors associated with responders to treatment with
tolvaptan are shown in Table 2. In univariate analysis, age, eGFR,
and kidney size were signiﬁcantly associated with responders.
Moreover, multivariate logistic analysis revealed that kidney size
was an independent determinant of responders (OR: 1.083,
p = 0.001, 95% CI 1.031–1.137).
Discussion
There were three major ﬁndings in the present study. First,
treatment with tolvaptan improved three conditions of heart
failure (increase in urine volume, improvement in NYHA functional
class, and decrease in CTR) in more than half of the patients with
ADHF. Second, eGFR, urine osmolality, and kidney size were
signiﬁcantly greater in responders to tolvaptan than in non-
responders. Third, multivariate logistic analysis revealed that
kidney size was independently associated with responders. These
ﬁndings indicate that treatment with tolvaptan for ADHF is
effective in patients with preserved kidney size.
In a stable hemodynamic state, serum creatinine or eGFR level
is a good parameter for renal function. However, in the ADHF
period, serum creatinine or eGFR level may not accurately reﬂect
renal function. For example, ﬂuid retention causes a higher eGFR
level than the original value, whereas a decrease in blood pressure
causes a lower eGFR level than the original value [16]. These results
might be involved in previous ﬁndings that serum creatinine or
eGFR is not sufﬁcient for predicting responders in HF patients
[7,8]. Interestingly, tolvaptan reduces the risk of worsening renal
function (deﬁned as serum creatinine elevation of 0.3 mg/dL or 50%
above baseline within 48 h) in patients with ADHF in high-risk
populations [17]. Thus, we think there is no need to hesitate to use
tolvaptan because serum creatinine is high or eGFR is low.Multivariate analysis
p-value OR 95% CI p-value
0.030 1.033 0.995–1.072 0.089
0.307
0.291
0.597
0.271
0.266
0.241
0.792
0.06
0.358
0.124
0.077
0.685
0.634
0.784
0.393
0.054
0.15
0.041 1.022 0.999–1.045 0.062
0.387
0.029 1.083 1.031–1.137 0.001
rain natriuretic peptide; eGFR, estimated glomerular ﬁltration rate.
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evaluation, and an atrophic kidney suggests progressive renal
failure. Kidney size is inﬂuenced by various factors including age,
sex, right and left sides, BMI, and absence or presence of
hypertension and diabetes mellitus [18,19]. In this study,
univariate and multivariate analyses revealed that kidney size
was an independent determinant of responders. The mean values
of normal kidney sizes assessed by longitudinal lengths in Japanese
are 9.8 cm on the right side and 10.6 cm on the left side [20]. Since
kidney size in non-responders to tolvaptan was 8.3  1.2 cm, their
kidneys were slightly atrophic. On the other hand, kidney size in
responders to tolvaptan was 9.3  1.1 cm. It has been reported that
kidney size is correlated to renal function [10]. These results indicate
that treatment with tolvaptan for ADHF is effective in patients with
preserved kidney size, which implies preserved renal reserve and
function of collecting tubules. Tolvaptan was not effective for patients
with atrophic kidneys. Furthermore, this study showed that
measurement of kidney size by computed tomography is a simple
method and provides important information including information
for predicting responders to tolvaptan.
Imamura et al. reported that maintained urine osmolality
before administration of tolvaptan and decrease in urine osmolali-
ty after 4–6 hours of tolvaptan administration predict responders
[7,8]. In their study, responders were deﬁned as patients with an
increase in urine volume during the ﬁrst 24 h after the start of
administration. In our study, baseline urine osmolality was also
signiﬁcantly higher in responders than in non-responders, and
eGFR was higher in responders than in non-responders. These
results indicate that maintained renal function including capacity
of ﬁltration and urinary concentration is an important factor for
response to tolvaptan.
We deﬁned responders on the basis of acute urine response and
remission of heart failure symptoms and signs assessed by NYHA
functional class and chest X-ray. NYHA class did not improve in
16 of the 98 patients with increasing urine volume. Therefore,
increase in urine volume is not sufﬁcient to deﬁne responders to
tolvaptan in a clinical setting. Furthermore, to prevent adverse
effects such as thirst and hypernatremia, it is necessary to observe
patients treated with tolvaptan without water restriction. Thus,
urine volume is affected by the quantity of water intake. Therefore,
we think it is not sufﬁcient to evaluate responders only by
increasing urine volume. We considered CTR as an index of
intravascular ﬂuid volume or congestion, and it might be better to
deﬁne responders on the basis of decrease in body weight or
decrease in inferior vena cava (IVC) diameter or transtricuspid
pressure gradient measured by echocardiography. Further studies
are needed to clarify this point.
Study limitations
The present study has several limitations. First, since other
therapeutic agents including an angiotensin-converting enzyme
inhibitor/angiotensin-receptor blocker and a b blocker were used
[21,22], the efﬁcacy of tolvaptan alone could not be precisely
evaluated. Second, kidney size is inﬂuenced by various factors
including age, sex, right and left sides, BMI, and absence or
presence of hypertension and diabetes mellitus [18,19]. Therefore,
it was necessary to perform univariate and multivariate analyses
including factors related to kidney size. In our study, we measured
kidney size by means of CT; however, in terms of radiation
exposure, this approach does not seem to be reimbursable.
Ultrasound should be the ﬁrst choice because it involves no
radiation exposure. Third, we included ADHF patients who
underwent CT at index admission. This is one of the selection
biases and had the possibility of inﬂuencing the results. Fourth, the
dose of tolvaptan was determined by each doctor, and we thereforecould not rule out the possibility that the dose of tolvaptan was not
sufﬁcient in non-responders. We can only state that there was no
signiﬁcant difference in the dose of tolvaptan between responders
and non-responders in this study.
A different study design, a larger prospective study, and
matching by propensity score for estimation of kidney size are
needed to conﬁrm the predictors of tolvaptan effectiveness.
Conclusions
Treatment with tolvaptan for ADHF is effective in more than
half of the patients. Kidney size was signiﬁcantly greater in
responders to tolvaptan than in non-responders and it was
independently associated with responders. Treatment with
tolvaptan for ADHF was effective in patients with preserved
kidney size, which implies preserved renal reserve and function of
collecting tubules.
Funding
This research received no grant from any funding agency in the
public, commercial, or not-for-proﬁt sectors.
Conﬂict of interest
None declared.
Acknowledgments
We thank Masayo Ohmori for her excellent technical assistance.
We wish to extend our appreciation to the investigators of the
Tolvaptan Registry.
Appendix
Tolvaptan Registry Scientiﬁc Advisory Committee
Ito H (chair), Nakamura K
Study investigators (7 hospitals)
Okayama University Graduate School of Medicine: Toda H,
Tokioka K, Hashimoto K, Nishii N, Miyoshi T, Kohno K,
Nakamura K, Ito H
Fukuyama City Hospital: Seiyama K, Kagawa K, Naito Y,
Tsushima S, Kawada S, Dan K, Watanabe A, Terasaka R,
Nakahama M
Ehime Prefectural Central Hospital: Kawai Y, Okayama H
National Hospital Organization Okayama Medical Center:
Miyaji K, Matsubara H
Mitoyo General Hospital: Koide Y, Ueeda M
Japanese Red Cross Society Himeji Hospital: Tachibana M,
Mukohara N
Sakakibara Heart Institute of Okayama: Yoshioka R, Yamamoto K
References
[1] JCS-Joint-Working-Group. Guidelines for treatment of acute heart failure (JCS
2011). Circ J 2013;77:2157–201.
[2] Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M,
Orlandi C. Vasopressin V2-receptor blockade with tolvaptan in patients with
chronic heart failure: results from a double-blind, randomized trial. Circula-
tion 2003;107:2690–6.
[3] Gheorghiade M, Konstam MA, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg
K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term
clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospi-
talized for heart failure: the EVEREST Clinical Status Trials. J Am Med Assoc
2007;297:1332–43.
[4] Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical
pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011;25(Suppl.
1):S57–65.
H. Toda et al. / Journal of Cardiology 67 (2016) 177–183 183[5] Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E,
Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi
K, Nakamura M, et al. Short-term effects of low-dose tolvaptan on hemody-
namic parameters in patients with chronic heart failure. J Cardiol 2012;60:
462–9.
[6] Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol
2011;7:151–61.
[7] Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki
H, Hatano M, Yao A, Kyo S, Nagai R. Novel criteria of urine osmolality effectively
predict response to tolvaptan in decompensated heart failure patients –
association between non-responders and chronic kidney disease. Circ J
2013;77:397–404.
[8] Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H,
Shiga T, Hatano M, Yao A, Kyo S, Komuro I. Urine osmolality estimated using
urine urea nitrogen, sodium and creatinine can effectively predict response to
tolvaptan in decompensated heart failure patients. Circ J 2013;77:1208–13.
[9] Costello-Boerrigter LC, Boerrigter G, Burnett Jr JC. Pharmacology of vasopressin
antagonists. Heart Fail Rev 2009;14:75–82.
[10] Moghazi S, Jones E, Schroepple J, Arya K, McClellan W, Hennigar RA, O’Neill
WC. Correlation of renal histopathology with sonographic ﬁndings. Kidney Int
2005;67:1515–20.
[11] ACR–SPR. Practice parameter for the performance of computed tomography
(CT) of the abdomen and computed tomography (CT) of the pelvis. Res. 32-
2011, Amended 2014 (Res. 39). Practice Parameters and Technical Standards.
American College of Radiology; 2014 , http://www.acr.org//media/ACR/
Documents/PGTS/guidelines/CT_Abdomen_Pelvis.pdf.
[12] Toh N, Morita H, Nagase S, Taniguchi M, Miura D, Nishii N, Nakamura K, Ohe T,
Kusano KF, Ito H. Atrial electrophysiological and structural remodeling in
high-risk patients with Brugada syndrome: assessment with electrophysiolo-
gy and echocardiography. Heart Rhythm 2010;7:218–24.[13] Japanese Society of Nephrology. Evidence-based practice guideline for the
treatment of CKD. Clin Exp Nephrol 2009;13:537–66.
[14] Giamouzis G, Sui X, Love TE, Butler J, Young JB, Ahmed A. A propensity-
matched study of the association of cardiothoracic ratio with morbidity and
mortality in chronic heart failure. Am J Cardiol 2008;101:343–7.
[15] Fukuta H, Ohte N, Brucks S, Carr JJ, Little WC. Contribution of right-sided heart
enlargement to cardiomegaly on chest roentgenogram in diastolic and systolic
heart failure. Am J Cardiol 2007;99:62–7.
[16] Dupont M, Mullens W, Finucan M, Taylor DO, Starling RC, Tang WH. Deter-
minants of dynamic changes in serum creatinine in acute decompensated
heart failure: the importance of blood pressure reduction during treatment.
Eur J Heart Fail 2013;15:433–40.
[17] Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, Ohno M,
Matsumura A, Hashimoto Y. Tolvaptan reduces the risk of worsening renal
function in patients with acute decompensated heart failure in high-risk
population. J Cardiol 2013;61:169–74.
[18] Glodny B, Unterholzner V, Taferner B, Hofmann KJ, Rehder P, Strasak A,
Petersen J. Normal kidney size and its inﬂuencing factors – a 64-slice MDCT
study of 1.040 asymptomatic patients. BMC Urol 2009;9:19.
[19] Buchholz NP, Abbas F, Biyabani SR, Afzal M, Javed Q, Rizvi I, Talati J. Ultraso-
nographic renal size in individuals without known renal disease. J Pak Med
Assoc 2000;50:12–6.
[20] Kojima K. CT of the kidney in chronic renal failure. J Okayama Med Assoc
2010;100:857–72.
[21] Lang CC, Struthers AD. Targeting the renin–angiotensin–aldosterone system in
heart failure. Nat Rev Cardiol 2013;10:125–34.
[22] Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto
M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T.
Carvedilol decreases elevated oxidative stress in human failing myocardium.
Circulation 2002;105:2867–71.
